Clinical Trial Update: Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer [Phase 2]

View source ↗

Summary

This Phase 2 study evaluated the Akt inhibitor MK-2206 in patients with recurrent or metastatic nasopharyngeal squamous cell carcinoma. The trial has completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Nasopharyngeal Squamous Cell Carcinoma

Drugs mentioned

• MK-2206 (MK-2206)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx | Phase 2 | Status: COMPLETED | Results posted: 2015-01-08